Cardlytics Proceeds Revenue Contraction Amidst Worsening Economics (NASDAQ: CDLX)

.Financial writer highly recommends selling Cardlytics, Inc. because of decreasing device economics, revenue challenges, as well as unfavorable financial styles. Click on for this CDLX update.